Tirzepatide, a dual-agonist peptide, has shown significant results with a 22.5% weight loss over 72 weeks at a 15 mg dose (Jastreboff et al., NEJM), making it one of the most effective therapies for obesity
This section will explore whether semaglutide can have an impact on eye health, particularly in relation to glaucoma
The primary and key secondary outcomes in included studies PIONEER 1 to 6, 8 and 9 were based on objective outcomes, such as A1C, body weight, and time to first occurrence of MACE, and therefore would be less impacted by potential bias introduced from the open-label study designs or inferred randomization
Together: These two peptides form a powerful regenerative duo combining BPC-157s tissue-protective effects with TB-500s cell-mobilizing action for whole-body healing, faster recovery, and reduced inflammation
Timing and Administration Optimization Injection timing can influence both effectiveness and side effects